Literature DB >> 17653117

Mechanisms of disease: Toll-like receptors in cardiovascular disease.

Stefan Frantz1, Georg Ertl, Johann Bauersachs.   

Abstract

The innate immune system detects highly conserved, relatively invariant structural motifs of pathogens. Toll-like receptors (TLRs) have been identified as the primary innate immune receptors. TLRs distinguish between different patterns of pathogens and activate a rapid innate immune response; however, TLRs can also be activated by host-derived molecules. In addition to being expressed in immune cells, TLRs are expressed in other tissues, such as those of the cardiovascular system. TLRs could, therefore, be a key link between cardiovascular disease development and the immune system. Indeed, evidence that TLR activation contributes to the development and progression of atherosclerosis, cardiac dysfunction in sepsis, and congestive heart failure, is convincing. Although much has been learned about TLR activation in cellular components of the cardiovascular system, the role individual TLR family members have in the pathophysiology of cardiovascular diseases and hence in clinical practice remains to be defined. Here we review the rapid progress that has been made in this field, which has improved our understanding of vascular as well as myocardial TLR function in basic and clinical science.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653117     DOI: 10.1038/ncpcardio0938

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  117 in total

Review 1.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

2.  Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

Authors:  Yong-yi Wang; Sha Liu; Feng Lian; Wen-gang Yang; Song Xue
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

Review 3.  Role of reactive oxygen and nitrogen species in the vascular responses to inflammation.

Authors:  Peter R Kvietys; D Neil Granger
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

Review 4.  Therapeutic targeting of innate immunity in the failing heart.

Authors:  Veli K Topkara; Sarah Evans; Weili Zhang; Slava Epelman; Lora Staloch; Philip M Barger; Douglas L Mann
Journal:  J Mol Cell Cardiol       Date:  2010-11-10       Impact factor: 5.000

Review 5.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

6.  Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury.

Authors:  Aaron M Abarbanell; Yue Wang; Jeremy L Herrmann; Brent R Weil; Jeffrey A Poynter; Mariuxi C Manukyan; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

7.  Prostaglandin E2 and an EP4 receptor agonist inhibit LPS-Induced monocyte chemotactic protein 5 production and secretion in mouse cardiac fibroblasts via Akt and NF-κB signaling.

Authors:  Timothy D Bryson; Jacob Ross; Edward Peterson; Pamela Harding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-06-20       Impact factor: 3.072

8.  TLR4 activation induces nontolerant inflammatory response in endothelial cells.

Authors:  Wenmeng Wang; Minjie Deng; Xueting Liu; Wen Ai; Qizhu Tang; Jinyue Hu
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

9.  Helicobacter pylori vs coronary heart disease - searching for connections.

Authors:  Magdalena Chmiela; Adrian Gajewski; Karolina Rudnicka
Journal:  World J Cardiol       Date:  2015-04-26

Review 10.  Impact of notch signaling on inflammatory responses in cardiovascular disorders.

Authors:  Thibaut Quillard; Beatrice Charreau
Journal:  Int J Mol Sci       Date:  2013-03-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.